Skip to main content
. 2020 May 14;25(19):1900401. doi: 10.2807/1560-7917.ES.2020.25.19.1900401

Table 2. Relative vaccine effectiveness of high-dose vs standard dose influenza vaccination and mortality by influenza period, matched and adjusted using Cox proportional hazards model, among predominantly male, white, senior veterans, United States, 2012/13–2014/15 (n = 569,552).

Population Season Influenza/pneumonia cause of death Cardiorespiratory cause of death
Influenza period
Early High Late Early High Late
rVE % (95% CI) rVE % (95% CI)
All subjects 2012/13 0
(−56–36)
23
(−83 to 67)
4
(−143 to 62)
5
(−41 to 37)
23
(13 to 32)
3
(−39 to 32)
2013/14 10
(−88 to 57)
32
(−17 to 60)
13
(−86 to 59)
7
(−8 to 20)
28
(19 to 35)
9
(−5 to 22)
2014/15 23
(−5 to 43)
47
(21 to 65)
16
(−46 to 52)
14
(8 to 20)
30
(23 to 36)
13
(2 to 22)
Pooled 17
(−3 to 37)
42
(24 to 59)
13
(−22 to 48)
13
(7 to 18)
27
(23 to 32)
11
(3 to 19)
Excluding subjects with greater than 5% predicted mortality 2012/13 −1
(−60 to 36)
22
(−79 to 73)
−5
(−696 to 86)
−4
(−130 to 53)
24
(−18 to 51)
−3
(−34 to 21)
2013/14 −2
(−124 to 53)
37
(−9 to 64)
1
(−119 to 55)
2
(−30 to 26)
21
(4 to 35)
0
(−28 to 22)
2014/15 6
(−165 to 67)
41
(9 to 55)
−8
(−389 to 76)
8
(−18 to 28)
31
(19 to 41)
7
(−13 to 24)
Pooled 1
(−44 to 46)
36
(10 to 62)
−4
(−98 to 89)
2
(−28 to 32)
25
(12 to 38)
1
(−12 to 15)

CI: confidence interval; rVE: relative vaccine effectiveness.